Lakewood-Amedex Biotherapeutics Inc. Common Stock

Zhongchao Inc. led healthcare gainers on Wednesday with a 191.84% surge to $4.29 following a 1-for-3 reverse share split to maintain Nasdaq compliance. Lakewood-Amedex Biotherapeutics advanced 83.33% to $3.41 after reporting that its antimicrobial candidate Nu-3 aligns with PACCARB goals by destroying bacterial membranes, positioning it as a promising treatment for antibiotic-resistant infections and infected diabetic foot ulcers. Arrowhead Pharmaceuticals jumped 19.03% to $88.70 after its Phase 3 SHASTA-3 and SHASTA-4 trials of Plozasiran met the primary endpoint of triglyceride reduction and showed a statistically significant reduction in acute pancreatitis in severe hypertriglyceridemia patients, with an sNDA planned by year-end. LB Pharmaceuticals gained 10.93% to $35.84 after accelerating the topline data readout for its Phase 3 NOVA-2 trial of LB-102 in schizophrenia to the first half of 2027. Other notable movers included Advanced Biomed up 73.02% on no specific news, Satellos Bioscience up 14.72%, and DarioHealth up 12.86% after pricing a $23.5 million registered direct offering.